Radiotherapy plus chemo for WNT medulloblastoma in children
Part of Cancer clinical trials.
This study tests whether adding a specific brain/spinal radiation plan (focused radiation plus low-dose spinal coverage) followed by chemotherapy works well for children with newly diagnosed WNT medulloblastoma after surgery. It targets kids whose remaining tumor after surgery is small and who have no spread to the spine or fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 3 and 15 years old (starting after your 3rd birthday and before your 16th birthday).
- Have newly diagnosed WNT-pathway medulloblastoma based on tumor testing.
- After surgery, the remaining tumor seen on MRI is smaller than 1.5 square centimeters.
- No tumor spread to the spine or brain fluid: MRI of brain and spine plus a lumbar puncture test for CSF cells.
- Be able to start the next treatment (radiation/chemo) within 6 weeks after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
This study tests a new way to treat children with brain tumors using proton radiation (a precise type of radiation). It's designed to help the radiation target the tumor while protecting the spine and its ability to grow normally.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Hear when a new Medulloblastoma, WNT-activated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.